Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Zschäbitz S, Bhatti I, Casuscelli J, Pachmayr LO, Büttner T, Elegeert T, Holzwarth N, Rodler S, Hennig M, Rinderknecht E, Dib M, Schlack K, Darr C, Volk AL, Schmucker P, Zengerling F, Paffenholz P, Heil J, Erne E, Mandal S, Wessels F, Busse TM, Seidl D, Foller S, Höllein A, Nestler T, Gratzke C, Rhode L, Kohler J, Niegisch G, Seitz AK, Heinzelbecker J, Klümper N, Retz M, Grünwald V, Aydogdu C, Schnabel MJ

Open source

DOI: 10.1007/s00262-026-04448-2
Published: 2026 Jul 12
Container: Cancer immunology, immunotherapy : CII
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-026-04448-2,
  title = {Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).},
  author = {Zschäbitz S and Bhatti I and Casuscelli J and Pachmayr LO and Büttner T and Elegeert T and Holzwarth N and Rodler S and Hennig M and Rinderknecht E and Dib M and Schlack K and Darr C and Volk AL and Schmucker P and Zengerling F and Paffenholz P and Heil J and Erne E and Mandal S and Wessels F and Busse TM and Seidl D and Foller S and Höllein A and Nestler T and Gratzke C and Rhode L and Kohler J and Niegisch G and Seitz AK and Heinzelbecker J and Klümper N and Retz M and Grünwald V and Aydogdu C and Schnabel MJ},
  year = {2026},
  journal = {Cancer immunology, immunotherapy : CII},
  doi = {10.1007/s00262-026-04448-2},
  url = {https://doi.org/10.1007/s00262-026-04448-2}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
AU  - Zschäbitz S
AU  - Bhatti I
AU  - Casuscelli J
AU  - Pachmayr LO
AU  - Büttner T
AU  - Elegeert T
AU  - Holzwarth N
AU  - Rodler S
AU  - Hennig M
AU  - Rinderknecht E
AU  - Dib M
AU  - Schlack K
AU  - Darr C
AU  - Volk AL
AU  - Schmucker P
AU  - Zengerling F
AU  - Paffenholz P
AU  - Heil J
AU  - Erne E
AU  - Mandal S
AU  - Wessels F
AU  - Busse TM
AU  - Seidl D
AU  - Foller S
AU  - Höllein A
AU  - Nestler T
AU  - Gratzke C
AU  - Rhode L
AU  - Kohler J
AU  - Niegisch G
AU  - Seitz AK
AU  - Heinzelbecker J
AU  - Klümper N
AU  - Retz M
AU  - Grünwald V
AU  - Aydogdu C
AU  - Schnabel MJ
PY  - 2026
JO  - Cancer immunology, immunotherapy : CII
DO  - 10.1007/s00262-026-04448-2
UR  - https://doi.org/10.1007/s00262-026-04448-2
ER  -

APA

S, Z., I, B., J, C., LO, P., T, B., T, E., N, H., S, R., M, H., E, R., M, D., K, S., C, D., AL, V., P, S., F, Z., P, P., J, H., E, E., S, M., F, W., TM, B., D, S., S, F., A, H., T, N., C, G., L, R., J, K., G, N., AK, S., J, H., N, K., M, R., V, G., C, A., & MJ, S. (2026). Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04448-2

Source records

pubmed · retrieved 2026-09-26T03:17:24.331Z